| Title: |
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol |
| Authors: |
S. M. Gillessen, L.; James, N. D.; Sachdeva, A.; El-Taji, O.; Abdel-Aty, H.; Adler, A. I.; Amos, C.; Attard, G.; Varughese, M.; Gale, J.; Brown, S.; Srihari, N.; Birtle, A. J.; Brown, M.; Chan, K.; Chowdhury, S.; Cross, W.; Dearnaley, D. P.; Din, O.; Dutey-Magni, P.; Gilbert, D. C.; Gilson, C.; Gray, S.; Grist, E.; Hofmann, U.; Hudson, A. M.; Jain, Y.; Jeyasangar, G.; Jones, R.; Kayani, M.; Langley, R. E.; Malik, Z.; Mason, M. D.; Matheson, D.; McAlpine, C.; Macnair, A.; Millman, R.; Murphy, C.; Padden-Modi, M.; Parikh, O.; Parker, C.; Rush, H.; Russell, M.; Srinivasan, R.; Sundar, S.; Tanguay, J. S.; Turco, F.; Williams, P.; Sydes, M. R.; Parmar, M. K. B.; Brown, L. C.; Clarke, N. W. |
| Contributors: |
Oncology (Department of); Varughese, Mohini; Srinivasan, Rajaguru |
| Publisher Information: |
Elsevier |
| Publication Year: |
2026 |
| Collection: |
RD&E Research Repository (Royal Devon and Exeter NHS Foundation Trust) |
| Subject Terms: |
Humans; Male; Metformin/therapeutic use/adverse effects/administration & dosage; Prostatic Neoplasms/drug therapy/pathology/mortality; Androgen Antagonists/adverse effects/therapeutic use/administration & dosage; Aged; Adenocarcinoma/drug therapy/secondary; Hypoglycemic Agents/therapeutic use; Middle Aged; Randomized Controlled Trials as Topic; Neoplasm Metastasis; Nitriles; Thiohydantoins/administration & dosage; Glycated Hemoglobin/metabolism; Multicenter Studies as Topic |
| Description: |
BACKGROUND: Metformin is a widely used anti-diabetic drug. Several studies have suggested that metformin has anticancer activity in some malignancies, including prostate cancer. Metformin might also mitigate the adverse metabolic effects of androgen-deprivation therapy (ADT). We hypothesised that metformin might improve survival in patients with metastatic hormone-sensitive prostate cancer and reduce metabolic complications associated with ADT. METHODS: The STAMPEDE multi-arm, multi-stage, randomised phase 3 trial recruited patients with high-risk locally advanced or metastatic adenocarcinoma of the prostate staged by conventional imaging with isotope bone and CT scanning. This publication reports findings for the most recent STAMPEDE research question, testing the addition of metformin to standard of care for non-diabetic (glycated haemoglobin [HbA1c] |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
https://pmc.ncbi.nlm.nih.gov/articles/pmid/40639383/; The Lancet. Oncology; PMC12303861; https://hdl.handle.net/11287/623986 |
| DOI: |
10.1016/s1470-2045(25)00231-1 |
| Availability: |
https://hdl.handle.net/11287/623986; https://doi.org/10.1016/s1470-2045(25)00231-1 |
| Rights: |
Copyright © 2025 The Author(s). |
| Accession Number: |
edsbas.ED8F56BE |
| Database: |
BASE |